Congratulations to Dr. Marie Hudson on her appointment as McGill Division Director of Rheumatology. We extend our sincere gratitude to Dr. Laeora Berkson for her exceptional leadership as former Division Director, guiding the division through the transition and contributing greatly to its ongoing success.
Dr. Hudson is a rheumatologist at the Jewish General Hospital and a clinician-investigator at the Lady Davis Institute. She is a founding member of the multi-centered Canadian Scleroderma Research Group (CSRG) which has recruited more than 1700 patients over 15 years. She has worked on a broad range of projects and is now exploring the therapeutic potential of cellular therapies for scleroderma.
Modeled on the CSRG, Dr. Hudson launched the Canadian Inflammatory Myopathy Study (CIMS), a multi-centered cohort of patients with autoimmune myositis. CSRG and CIMS have become internationally recognized research programs. Dr. Hudson also pursues research in rheumatoid arthritis (RA) and is leading an inter-divisional study on precision care for RA. Finally, she has an interest in immune-related adverse events (irAE) secondary to immune checkpoint inhibitors. Locally, she established the Montreal Immune-Related Adverse Event (MIRAE) Biobank. Nationally, she is co-leading a multi-centered cohort study of cancer patients who develop rheumatic irAE, the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO) study. Dr. Hudson also pursues a number of other scholarly activities, including serving as co-director of the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) from 2019-2024.